- Home
- EAF vs PRQR Comparison
EAF vs PRQR Comparison
Compare EAF & PRQR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | EAF | PRQR |
|---|---|---|
| Founded | 1886 | 2012 |
| Country | United States | Netherlands |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 246.3M | 262.5M |
| IPO Year | 2018 | 2014 |
Fundamental Metrics
Financial Performance| Metric | EAF | PRQR |
|---|---|---|
| Price | $12.14 | $1.39 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 4 | 9 |
| Target Price | ★ $9.00 | $7.78 |
| AVG Volume (30 Days) | 582.1K | ★ 934.7K |
| Earning Date | 10-23-2026 | 11-09-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $504,134,000.00 | N/A |
| Revenue This Year | $2.85 | $8.25 |
| Revenue Next Year | $20.35 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $4.92 | $1.20 |
| 52 Week High | $19.72 | $2.81 |
Technical Indicators
Market Signals| Indicator | EAF | PRQR |
|---|---|---|
| Relative Strength Index (RSI) | 70.56 | 37.64 |
| Support Level | $5.79 | N/A |
| Resistance Level | $19.72 | $1.99 |
| Average True Range (ATR) | 0.87 | 0.10 |
| MACD | 0.43 | 0.00 |
| Stochastic Oscillator | 99.05 | 33.00 |
Price Performance
Historical ComparisonAbout EAF GrafTech International Ltd.
GrafTech International Ltd is a manufacturer of high-quality graphite electrode products essential to the production of EAF steel and other ferrous and non-ferrous metals. The company has only reportable segment, Industrial Materials, is comprised of its two product categories: graphite electrodes and petroleum needle coke products used as raw material in the production of graphite electrodes.
About PRQR ProQR Therapeutics N.V.
ProQR Therapeutics NV is a biopharmaceutical company. It discovers and develops RNA therapeutics for patients with severe genetic rare diseases such as cystic fibrosis, Leber congenital amaurosis type 10, and dystrophic epidermolysis bullosa. The only reportable segment of the company is the discovery and development of different, RNA-based therapeutics. Geographically, the company operates in United States.